GLP-1 drugs delivered to your door: what LillyDirect removes

Eli Lilly stopped negotiating with the PBS in April 2026. The consequence is that Mounjaro — their tirzepatide-based GLP-1 medication — sits outside the subsidy scheme that makes most medicines affordable for Australians. Patients who want it pay full private price, which puts it out of reach for many and into a commercially motivated distribution experiment for the rest.

LillyDirect is that experiment. The platform launched in Australia in late September 2026, allowing patients with an e-script to have their tirzepatide shipped directly to their home after an online pharmacist reviews the prescription. No trip to the chemist. A partnership with digital health company Evermed and licensed online pharmacies handles the back end. Lilly Australia’s General Manager framed it as complementing GP care and improving access to “competitive pricing.”

What Lilly presents as a supply-chain efficiency, the two major professional bodies see as a safety problem with a specific shape.

What GPs are actually worried about

RACGP President Dr Michael Wright’s concern is precise: people with eating disorders have been accessing GLP-1 medications away from their usual GP. That sentence contains a clinical problem worth unpacking.

GLP-1 receptor agonists like tirzepatide are prescribed for weight management. Their mechanism involves slowing gastric emptying and reducing appetite — effects that are therapeutic in metabolic disease and potentially dangerous in someone with a history of restrictive eating, purging, or disordered food relationship. A pharmacist reviewing a script sent through an online platform likely does not have access to the eating disorder history that would change the risk calculation entirely. A GP who has known the patient for years almost certainly does.

The RACGP characterised the LillyDirect model as a “fragmented free-for-all” and called for regulatory oversight matching Australian pharmaceutical safety standards. The Pharmacy Guild, through President Trent Twomey, named it an “Americanisation of Australian health care” — pointing to a model where the commercial pathway has been permitted to disintermediate the face-to-face clinical relationship.

University of Sydney pharmacologist Professor Barbara Mintzes added a structural point that deserves its own paragraph: Eli Lilly has “an interest in keeping people on the medicine”. That is not an accusation of bad faith. It is a statement about what incentive alignment looks like when a manufacturer controls both the drug and the dispensing pathway. The interests are misaligned in a direction that increases risk for patients whose clinical complexity the platform was not designed to detect.

AHPRA has previously flagged issues with incorrect prescribing of GLP-1 medications via telehealth services — the very pathway LillyDirect explicitly directs new patients toward to obtain their e-scripts. The regulatory concern is not hypothetical.

Both-and: the access problem is real

None of this means that LillyDirect is straightforwardly harmful, or that every patient accessing Mounjaro through the platform will come to harm. The access argument is legitimate. Outside the PBS, tirzepatide is expensive and difficult to obtain through conventional pharmacy channels. The medication has genuine clinical evidence behind it for weight management and metabolic health outcomes. If the choice narrows to an imperfect access pathway or no access at all, some patients will rationally choose the imperfect pathway.

The structural critique from general practice is not that patients shouldn’t be able to access GLP-1 medications. It is that a distribution model where the manufacturer controls both the drug and the dispensing pathway — while bypassing the clinical layer that catches contraindications — represents a commercial interest operating in the space where a clinical safeguard belongs.

The question of whether Australian regulation is adequate for direct-to-consumer dispensing of potent weight-management drugs is, right now, an open one.

2 cents

If you are considering or already using a GLP-1 medication, the channel you access it through is not a bureaucratic detail. It has clinical content. A GP who has your full history — including eating disorder history, current medications, gastrointestinal conditions — is structurally more likely to catch a contraindication than a pharmacist reviewing a script through a platform optimised for convenience and scale.

That doesn’t mean the platform is illegal or that everyone who uses it will experience a preventable adverse event. It means the question worth asking, when choosing how you access any high-potency medication, is: who in this pathway actually knows me?

Verdict: maybe — watch this.

---

Sources cited

1. Eli Lilly launches Mounjaro home delivery service — newsGP, RACGP
2. Doctors condemn big pharma’s move to dispense GLP-1s to your door — ABC News Australia